Lipocine Inc.
LPCN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -81.6% | 563.6% | -97.3% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 100% | -243.1% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -2,919.5% | -383.4% | -2,210.2% | 44.7% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -2,781.5% | -354.1% | -1,986.8% | 51% |
| EPS Diluted | -0.59 | -0.41 | -0.35 | 0.32 |
| % Growth | -43.9% | -17.1% | -209.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |